Prader-Willi Syndrome (PWS) is a complex genetic disorder characterized by developmental and 19 growth abnormalities, insatiable appetite, and excessive eating (hyperphagia). The underlying cause 20 of hyperphagia in PWS is currently unknown, however, elevated levels of the peptide hormone 21 ghrelin is believed to contribute. Recently, ghrelin-reactive autoantibodies (isotype IgG) were 22 identified in non-genetic obesity. These autoantibodies act as ghrelin carrier proteins and potentiate its 23 orexigenic effects. Here, we describe the identification of ghrelin-reactive autoantibodies in a cohort 24 of 16 children with PWS. In comparison to unaffected siblings, autoantibody levels are significantly 25 increased in PWS children. We further show that autoantibody levels are unaffected by food intake, 26 unlike plasma ghrelin which declines postprandially in both groups. Critically, we also demonstrate 27 that the autoantibodies bind the major circulating ghrelin isoforms, unacylated ghrelin, which does not 28 stimulate appetite, and the orexigen acylated ghrelin. In excess, unacylated ghrelin may compete with 29 acylated ghrelin for autoantibody binding. Taken together, this is the first report on ghrelin-reactive 30 antibodies in a pediatric population, and the first to demonstrate that the antibodies do not 31 discriminate between orexigenic and non-orexigenic ghrelin isoforms. Our work suggests that ghrelin 32 autoantibodies can be targeted using non-orexigenic forms of ghrelin, thereby providing a novel 33 therapeutic target for PWS and for obesity in general. 
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Introduction 37
Prader-Willi Syndrome (PWS) is the most common genetic cause of obesity in children and is 38 characterized by developmental and growth abnormalities, insatiable appetite and impaired satiety [1] . 39 PWS patients also exhibit high levels of the orexigenic peptide hormone ghrelin. The two major forms 40 of ghrelin in the circulation are acyl ghrelin, which potently stimulates appetite and food-seeking 41 behaviour, and unacylated ghrelin (UAG), which has no effect on appetite [2-4]. Recently, ghrelin-42 reactive autoantibodies (isotype IgG) were identified in non-genetic obesity [5] . These autoantibodies 43 bind ghrelin reversibly, acting as carrier proteins that protect ghrelin from degradation and potentiate 44 its orexigenic effects [5] . Here, we sought to further explore this association by characterizing ghrelin 45 autoantibodies in children with PWS and non-affected sibling controls. 46
47

Methods 48
Sixteen children with PWS and 16 controls, matched for body mass index (BMI), were recruited to 49 the study. Plasma was collected after an overnight fast (baseline), and 10, 20, 30, 60 and 120 minutes 50 after a standardized mixed meal. Plasma acylated ghrelin levels were measured by ELISA (Human 51
Active Ghrelin ELISA, EZGRA-88K, Millipore). Ghrelin-reactive IgG levels were measured using an 52 adapted ELISA method [6] . To test specificity, and to determine if the autoantibodies also bind 53 unacylated ghrelin (UAG), samples were pre-absorbed overnight with 10 -6 M synthetic acylated 54 ghrelin or UAG (Mimotopes, Australia) prior to the ELISA. 55 56
Results
57
PWS children were shorter in stature and displayed reduced lean mass compared to controls (Table 1) . 58
Mean fasting plasma acylated ghrelin levels were significantly higher in the PWS group (P < 0.01, 59
Bonferonni-corrected two-way ANOVA; Figure 1A and Table 1 ), but postprandially ghrelin levels 60 were similar to those in the control group after 60 minutes. Unlike acylated ghrelin, postprandial 61 levels of ghrelin-reactive autoantibodies remained unchanged in both PWS and control children (P > 62 0.05; Figure 1B ). Children with PWS exhibited significantly higher fasting and postprandial levels of 63 plasma ghrelin-reactive autoantibodies than sibling controls (fasting comparison P < 0.0001, unpaired 64 Student's t-test; Figure 1B ). Pre-absorption of plasma with either acylated ghrelin or the non-65 orexigenic isoform, UAG, decreased autoantibody levels in the PWS and control groups (P < 0.001, 66 unpaired Student's t-test; Figure 1C, D) . 67
68
Discussion 69
To our knowledge, this study represents the first evidence of an association between Prader-Willi 70
Syndrome and ghrelin-reactive autoantibodies. Autoantibody levels were higher in children with PWS 71 compared to sibling controls, both after fasting and for two hours postprandially. Critically, we 72 demonstrate that, unlike plasma acylated ghrelin, ghrelin autoantibody levels remained constant 73 regardless of food intake status. 74
When considering the possible effects of ghrelin autoantibodies on the half-life of acylated 75 ghrelin, the relative levels of both acylated ghrelin and ghrelin IgG should be considered. Acylated 76 ghrelin levels decrease postprandially, while autoantibody levels remain constant. Therefore, the ratio 77 of acylated ghrelin to ghrelin-reactive autoantibodies is reduced. In PWS, the constant elevation of 78 ghrelin autoantibodies, which are believed to act as carrier proteins [5], could protect circulating 79 ghrelin from degradation, potentiating its effect and contributing to hyperphagia, a key feature of this 80 syndrome. Autoantibodies are thought to deliver acylated ghrelin to hypothalamic appetite-regulating 81 centers, either directly or via the ghrelin receptor (GHSR) expressed by vagal afferents neurons. Pre-82 incubation of plasma with supraphysiological levels of UAG reduced autoantibody levels detected in 83 plasma ex vivo in both the PWS and control groups, indicating that autoantibodies bind multiple 84 ghrelin isoforms and, that in excess, UAG may compete with acylated ghrelin for binding. Kinetic 85
studies have yet to be performed, however, it is possible that PWS patients exhibit distinct ghrelin-86 reactive antibody binding sites. Collectively, our data further implicate alterations of the ghrelin axis 87 in PWS, and suggest that ghrelin autoantibodies can be targeted using non-orexigenic forms of 88 ghrelin, thereby providing a novel therapeutic target for PWS and other ghrelin-associated disorders. 89 
